Contrast-induced nephropathy and biomarkers
Keywords:
contrast-induced nephropathy, iodinated contrast media, acute kidney injury (aKi), biomarker, neutrophil gelatinase-associated lipocalin (ngal)Abstract
Technological advances in diagnostic medical imaging techniques have contributed to an everincreasing number of individuals being exposed to iodinated contrast media. Despite its relatively good safety recommendations, some patients develop acute renal injury after administration of these contrast media. This phenomenon is called contrast-induced nephropathy (CIN) and is a common and potentially serious complication that normally occurs in patients with higher risk for development of acute kidney injury. Recently, many investigators have been intensively examining possible biomarker molecules for early diagnosis of this disease. Nowadays, the biomarker molecule that is becoming most promising is a protein called Nevtrophil gelatinase–associated lipocalin (NGAL), whose concentration increases very quickly in both urine and plasma after structural renal injury and even before functional renal failure. This would permit timely and adequate adjustment of interventions for the prevention of CIN: hydration and forced diuresis.
Downloads
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
